Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) EBT (2020 - 2025)

GeneDx Holdings has reported EBT over the past 6 years, most recently at -$18.2 million for Q4 2025.

  • Quarterly results put EBT at -$18.2 million for Q4 2025, down 436.72% from a year ago — trailing twelve months through Dec 2025 was -$21.1 million (up 59.84% YoY), and the annual figure for FY2025 was -$21.1 million, up 59.84%.
  • EBT for Q4 2025 was -$18.2 million at GeneDx Holdings, down from -$7.4 million in the prior quarter.
  • Over the last five years, EBT for WGSWW hit a ceiling of $32.7 million in Q3 2021 and a floor of -$308.7 million in Q4 2022.
  • Median EBT over the past 5 years was -$34.8 million (2021), compared with a mean of -$54.7 million.
  • Biggest five-year swings in EBT: skyrocketed 157.81% in 2021 and later plummeted 668.12% in 2022.
  • GeneDx Holdings' EBT stood at -$40.2 million in 2021, then plummeted by 668.12% to -$308.7 million in 2022, then surged by 91.52% to -$26.2 million in 2023, then surged by 120.68% to $5.4 million in 2024, then tumbled by 436.72% to -$18.2 million in 2025.
  • The last three reported values for EBT were -$18.2 million (Q4 2025), -$7.4 million (Q3 2025), and $10.6 million (Q2 2025) per Business Quant data.